Fostemsavir: 96-week follow-up in people with multi-drug resistance
24 July 2019. Related: Conference reports, Antiretrovirals.
Antiretrovirals
Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96
24 July 2019. Related: Conference reports, Antiretrovirals.
Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study
24 July 2019. Related: Conference reports, Antiretrovirals.
IAS 2019: late breaker highlights to look for
17 July 2019. Related: Conference reports, Antiretrovirals.
HIV pipeline report 2019
17 July 2019. Related: Special reports, Supplements, Pipeline report, Fit for purpose, Antiretrovirals.
Dolutegravir/lamivudine approved as dual HIV combination in EU
17 July 2019. Related: Antiretrovirals.
Dual long-acting cabotegravir/rilpivirine injection submitted to FDA
30 April 2019. Related: Antiretrovirals.
Dolutegravir/3TC dual FDC (Dovato) approved in the US and given positive opinion in the EU
30 April 2019. Related: Antiretrovirals.
Maturation inhibitor GSK’232 reduces viral load by –1.5 log at day 10
28 March 2019. Related: Conference reports, Antiretrovirals.
Capsid inhibitor GS-6207 shows potential for 3-monthly injections
28 March 2019. Related: Conference reports, Antiretrovirals.
First phase 1 results from bNAb PGT121 in HIV positive people
28 March 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies
28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.
Same-day ART is effective in San Francisco Rapid-ART clinic
28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.
Phase 3 results with dual therapy cabotegravir/rilpivirine long-acting injections: ATLAS and FLAIR studies
12 March 2019. Related: Conference reports, Antiretrovirals.
FDA approves generic TDF/3TC for use in the US
12 December 2018. Related: Antiretrovirals.
Doravirine (Pifeltro) and doravirine/TDF/3TC FDC (Delstrigo) approved in Europe
1 December 2018. Related: Antiretrovirals.
Viral dynamics of dolutegravir-based dual versus triple ART
13 November 2018. Related: Conference reports, Antiretrovirals.
Ibalizumab: 48-week phase 3 results in 27 participants with MDR HIV
13 November 2018. Related: Conference reports, Antiretrovirals.
Fostemsavir: 48-week phase 3 results from BRIGHTE study
13 November 2018. Related: Conference reports, Antiretrovirals.
Dolutegravir non-inferior to low dose efavirenz in real-life African study conducted in Cameroon
13 November 2018. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dual bNAb maintains viral suppression for median 21 weeks off-ART
13 November 2018. Related: Conference reports, Antiretrovirals, Treatment strategies.
Cabotegravir levels can be detected several years: PK tail to be covered by oral PrEP
13 November 2018. Related: Conference reports, Antiretrovirals.
FDA updates rilpivirine label for use during pregnancy
13 November 2018. Related: Antiretrovirals.
Dolutegravir/lamividune FDC submitted to EMA and FDA
19 October 2018. Related: Antiretrovirals.
English court finds in favour of access to generic TDF/FTC
19 September 2018. Related: Antiretrovirals, HIV prevention and transmission, Other news.
FDA approves doravirine (Pifeltro) and new FDC with TDF/3TC (Delstrigo) in the US
19 September 2018. Related: Antiretrovirals.
FDA update labels for dolutegravir and dolutegravir-based FDCs to reflect potential risk of neural tube defects
19 September 2018. Related: Antiretrovirals.
Top-line phase 3 results released for cabotegravir/rilpivirine long-acting injections
24 August 2018. Related: Antiretrovirals.
Interactions between oral anticoagulants and Genvoya, Stribild and cobicistat: FDA label updates
24 August 2018. Related: Antiretrovirals, PK and drug interactions.
DTG/3TC dual therapy is non-inferior to triple-ART in GEMINI study
3 August 2018. Related: Conference reports, Antiretrovirals.
Superior efficacy with dolutegravir-based ART compared with other regimens at 6 months: real-world data from Brazil
3 August 2018. Related: Conference reports, Antiretrovirals, Treatment access.
Fit for purpose: Antiretroviral treatment optimisation July 2018
23 July 2018. Related: Special reports, Supplements, Pipeline report, Fit for purpose, Antiretrovirals.
HIV pipeline 2018: full version
11 July 2018. Related: Special reports, Supplements, Pipeline report, Antiretrovirals.
Bictegravir/FTC/TAF (Biktarvy) approved in Europe
11 July 2018. Related: Antiretrovirals.
New contraindication against using darunavir/cobicistat during pregnancy
29 June 2018. Related: Treatment alerts, Antiretrovirals.
China approves albuvirtide: a once-weekly injectable entry inhibitor
29 June 2018. Related: Antiretrovirals.
Single dose PRO140 mAb reduces viral load by 0.5 log copies/mL in people with multidrug resistance
29 June 2018. Related: Antiretrovirals.
EMA approves dolutegravir/rilpivirine (Juluca) in Europe as dual-therapy HIV switch option
8 June 2018. Related: Antiretrovirals.
Meta-analysis of TAF vs TDF in boosted vs unboosted regimens
1 May 2018. Related: Conference reports, Antiretrovirals.
Meta-analysis of dolutegravir in naive, experienced and switch studies
1 May 2018. Related: Conference reports, Antiretrovirals.
Drug cost savings from routine use of generic ARVs: safety and efficacy in practice
1 May 2018. Related: Conference reports, Antiretrovirals, Treatment access.
Ibalizumab 24-week phase 3 results and susceptibility to drug-resistant HIV
30 March 2018. Related: Conference reports, Antiretrovirals.
Bictegravir at CROI 2018: switching studies and drug resistance analyses
14 March 2018. Related: Conference reports, Antiretrovirals, Drug resistance.
FDA approves ibalizumab in the US to treat multidrug HIV resistance
14 March 2018. Related: Antiretrovirals.
FDA grants tentative approval to first DTG/FTC/TAF FDC
23 February 2018. Related: Antiretrovirals, Treatment access.
Bictegravir approved in the US in new integrase-inhibitor based FDC (Biktarvy)
9 February 2018. Related: Antiretrovirals.
US approve a lower-dose efavirenz (400 mg) based generic FDC (Simfi Lo)
9 February 2018. Related: Antiretrovirals.
ViiV announces phase 3 study switching to dolutegravir/3TC dual therapy from TAF-containing ART
9 February 2018. Related: Antiretrovirals, Research studies.
US darunavir label updated: drug interactions and pregnancy
9 February 2018. Related: Antiretrovirals.
Doravirine FDC submitted to FDA in US: decision expected October 2018
22 January 2018. Related: Antiretrovirals.
FDA approves raltegravir for newborns
5 January 2018. Related: Antiretrovirals, Paediatric care.
Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results
28 November 2017. Related: Conference reports, Antiretrovirals.
D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets
28 November 2017. Related: Conference reports, Antiretrovirals.
Switch study shows F/TAF non-inferior to continuing abacavir/3TC
28 November 2017. Related: Conference reports, Antiretrovirals, Treatment strategies.
No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed
28 November 2017. Related: Conference reports, Antiretrovirals, PK and drug interactions.
ABX464 nudges viral reservoir but not time to viral rebound
28 November 2017. Related: Conference reports, Antiretrovirals, Cure-related research.
Long-acting ART for children is a deferred priority despite achievable dosing
28 November 2017. Related: Antiretrovirals, Paediatric care.
Coformulated dolutegravir plus rilpivirine approved in US (Juluca)
24 November 2017. Related: Antiretrovirals.
Darunavir-based single pill FDC approved in EU (Symtuza)
24 November 2017. Related: Antiretrovirals.
Dual therapy with darunavir/r plus lamivudine as first-line ART
1 October 2017. Related: Conference reports, Antiretrovirals.
Dual therapy with dolutegravir plus lamivudine as first-line ART
1 October 2017. Related: Conference reports, Antiretrovirals.
Once-daily raltegravir: 96-week results from the ONCEMRK study
1 October 2017. Related: Conference reports, Antiretrovirals.
Gilead uses voucher to speed FDA review of bictegravir
1 October 2017. Related: Antiretrovirals.
HIV pipeline drugs: IAS 2017 update
10 August 2017. Related: Conference reports, Antiretrovirals.
Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study
10 August 2017. Related: Conference reports, Antiretrovirals.